Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source
Makaleler > Tam Makale · 2017
Yazarlar: Hadiye ŞİRİN, Pierre Amarenco, Gregory W. Albers, Hans Denison, J. Donald Easton, Scott R. Evans, Peter Held, Michael D. Hill, Jenny Jonasson, Scott E. Kasner, Per Ladenvall, Kazuo Minematsu, Carlos A. Molina, Yongjun Wang, K. S. Lawrence Wong, S. Claiborne Johnston
STROKE, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2017, cilt 48, ss 2480-2492
DOI: 10.1161/strokeaha.117.017217
Özet
Background and Purpose-Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis.